The Effect of NLP on Pain Before Uterine Curettage Due to the Fetal Demise (NLP)

The Effect of Neurolingualistik Programming (NLP) on Pain Score, Fear of Pain and Pain Catastrophizing Before Uterine Curettage Due to the Fetal Demise

Pregnancy termination is a difficult and painful procedure can be done by medically or uterine curettage. Studies have been conducted to reduce the anxiety of women undergoing pregnancy termination, but there are no publications on topics such as anxiety, pain perception, and pain catastrophizing.

Neuro Linguistic Programming (NLP) has been called "the art and science of personal excellence", "the study of subjective experience". NLP helps us understand the difference between our actions that produce mediocre results or failure and those that require success or excellence.

NLP: "How do I do something I do well?", "How can I do it better?", "How can I gain skills that I admire in others? It addresses questions like ". It is important to note that NLP is not limited to observable behavior. Our way of thinking, that is, all experience and it also includes the mental processes that control our actions. By dealing with the entire structure of a person's experience (in fact, their motivation), it tries to shape the thought processes, emotions and beliefs that result in a behavior. It is especially about our communication with ourselves as well as with others.

No study was planned on pain and pain perception during pregnancy termination by uterine curettage by teaching the NLP technique to the patients.

Study Overview

• Status: Completed
• Conditions: Pain, Acute; Nursing Caries; Pregnancy Loss
• Intervention / Treatment: Behavioral: Neurolinguistic programming

Detailed Description

In this randomized controlled study, the group of patients who underwent uterine curettage with the indication of pregnancy termination in the Septic Service of the Department of Gynecology and Obstetrics of Şanlıurfa Training and Research Hospital will be divided into two groups and NLP training will be given before uterine curettage in a double-blind manner and VAS (visual pain scale) after uterine curettage. Evaluation will be made using the fear of pain scale-3 and the pain catastrophizing scale. NLP training will be given for approximately 20 minutes, and the group that will not receive NLP training will remain silent for 20 minutes. The results will be compared.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Şanlıurfa, Turkey
    • Sanliurfa Education and Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Over 18 years of age, non-pregnant, with an indication for pregnancy termination; Those who agreed to participate in the study, patients who understand and can speak Turkish

Exclusion Criteria:

• Patients who do not meet the inclusion criteria or who have had a previous pregnancy termination

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: control group; No intervention before, after pregnancy termination, pain scores and pain evaluation by questionnaires will be done.
Active Comparator: intervention; Neurolinguistic programme will be done before uterine curettage for pregnancy termination, after this, pain scores and pain evaluation by questionnaires will be done.	Behavioral: Neurolinguistic programming; In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
VAS score, pain perception scale and pain catastrophizing scales scores	pain scale	1 hour

Collaborators and Investigators

• Sponsor: Sanliurfa Education and Research Hospital
• Investigators: Study Chair: alev esercan, MD, Sanliurfa Education and Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 2, 2024
• Primary Completion (Actual): April 1, 2025
• Study Completion (Actual): April 4, 2025

Study Registration Dates

• First Submitted: July 2, 2024
• First Submitted That Met QC Criteria: July 2, 2024
• First Posted (Actual): July 9, 2024

Study Record Updates

• Last Update Posted (Actual): April 6, 2025
• Last Update Submitted That Met QC Criteria: April 4, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: pain; NLP; uterin curettage
• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Female Urogenital Diseases and Pregnancy Complications; Pregnancy Complications; Death; Fetal Death
• Other Study ID Numbers: 2024- Seah1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: by doi
• IPD Sharing Time Frame: six months
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No